Sugi Predict

Sugi Predict / Compounds / SCHEMBL358366

SCHEMBL358366

SCHEMBL358366

Cn1cnc2c(N3CCOCC3)nc(Cl)nc21

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.60
▸ CDK1 P06493 3/20 0.51
▸ YTHDC1 Q96MU7 1/20 0.49
▸ NT5E P21589 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HDAC1 Q13547 2/20 0.43
▸ MTOR P42345 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ TLR7 Q9NYK1 1/20 0.42
▸ PDE10A Q9Y233 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30366120 1.00 PIK3CA (0.60) PIK3CACDK1YTHDC1NT5ESMN1; SMN2
SCHEMBL13828421 0.85 ADORA1 (0.56) PIK3CACDK1YTHDC1SMN1; SMN2ADORA1
SCHEMBL7299820 0.83 CDK1 (0.51) PIK3CACDK1YTHDC1ADORA1TLR7
SCHEMBL13828322 0.83 PIK3CA (0.60) PIK3CAHDAC1MTORADORA1TLR7
SCHEMBL13828332 0.83 PIK3CA (0.71) PIK3CACDK1HDAC1MTORADORA1
SCHEMBL24955551 0.83 PIK3CA (0.60) PIK3CACDK1HDAC1MTORADORA1
SCHEMBL13828313 0.83 PIK3CA (0.60) PIK3CAHDAC1MTORADORA1TLR7
SCHEMBL30439903 0.82 TLR7 (0.50) PIK3CANT5ESMN1; SMN2HDAC1MTOR
SCHEMBL2395003 0.82 TLR7 (0.50) PIK3CANT5ESMN1; SMN2HDAC1MTOR
Hydrochloric Acid SCHEMBL7330227 0.82 CDK1 (0.50) PIK3CACDK1YTHDC1ADORA1TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
CN-118084941-A Pyridone substituent or derivative thereof, preparation method, application and pharmaceutical composition thereof 重庆文理学院 2024-05-28 — — CN disclosed
US-20240150358-A1 PURINES AND METHODS OF THEIR USE Kineta, Inc. 2024-05-09 — — US disclosed
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MONASH UNIVERSITY (AU) 2023-10-05 — — US disclosed
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MONASH UNIVERSITY (AU) 2023-10-05 — — US disclosed
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MONASH UNIVERSITY (AU) 2023-10-05 — — US disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
EP-4165045-A1 DUAL KINASE-BROMODOMAIN INHIBITORS Monash University (AU) 2023-04-19 — — EP disclosed
CN-102105474-A Purine PI3K inhibitor compounds and methods of use GENENTECH INC 2011-06-22 — — CN disclosed
EP-2279188-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2011-02-02 — — EP disclosed
WO-2010136491-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2010-12-02 — — WO disclosed
US-20100305096-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. 2010-12-02 — — US disclosed
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE HOFFMAN-LA ROCHE INC. 2010-12-02 — — US disclosed
WO-2010138589-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. (US) 2010-12-02 — — WO disclosed
EP-2215090-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-08-11 — — EP disclosed
US-20090318411-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2009-12-24 — — US disclosed
WO-2009146406-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-12-03 — — WO disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150358-A1 PURINES AND METHODS OF THEIR USE PNP, NUDT1, HPRT1 PIK3CA 3713/4885CDK1 2057/4885YTHDC1 2063/4885
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE PI4K2B, PIK3CA, PIK3R2 PIK3CA 2/4885CDK1 129/4885YTHDC1 4662/4885
US-20090318411-A1 PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, PIK3CG PIK3CA 1/4885CDK1 82/4885YTHDC1 3351/4885
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MAP2K2, BRPF3, BRDT PIK3CA 574/4885CDK1 99/4885YTHDC1 3744/4885
US-20100305096-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE PIK3CA, PIK3R2, PIK3CD PIK3CA 1/4885CDK1 145/4885YTHDC1 4612/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE PIK3CA 132/4885CDK1 1075/4885YTHDC1 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.